The theme of this year’s ESMO20 virtual meeting was “Bringing innovation to cancer patients,” one that definitely resonates at BSB where our focus is very much on “Bringing innovative science to life.”
In this latest post, we’re taking a closer look at data presented at ESMO20 by Prof Fabrice Barlesi (@Barlesi) on the first 100 patients enrolled in the biomarker part of the PIONeeR Project : Precision Immuno-Oncology for advanced Non-Small Cell Lung Cancer Patients with PD1(LC1) ICI Resistance (LBA53).
This work is part of the innovative Marseille Immunopôle (@Immunopole) collaboration between academia and industry in the South of France.
Back in 2016, BSB attended a scientific seminar in honor of the 40th anniversary of the Centre d’Immunologie de Marseille-Luminy (CIML), one of the academic partners and since then we’ve been following many of the innovative immuno-oncology companies such as Innate Pharma, HalioDx, and ImCheck Therapeutics, who form part of this biotech cluster.
Professor Fabrice Barlesi is now Medical Director at Gustave Roussy (link) and kindly took time out of his busy schedule to speak to BSB about the PIONeeR project.
Perhaps not surprisingly, finding out exactly why some people respond to checkpoint inhibitors in NSCLC and others do not is not quite as simple as it sounds.